Business Context and Reporting Period
This Form 8-K reports a change in control for Used Kar Parts, Inc. (OTCBB: UKAR), not Cardiff Oncology, Inc. The report date is February 26, 2004. The company was organized in April 2002 to develop an online marketplace for used car parts but has generated no revenue to date.
Key Financial Metrics
Based on the most recent Form 10-QSB (period ended October 31, 2003) cited in the filing:
- Total Assets: $1,582
- Accumulated Stockholders' Deficit: ($3,818)
- Revenue: $0 (No revenue reported from operations)
- Transaction Value: Panetta Partners, Ltd. purchased 2,000,000 shares (approx. 97% of outstanding stock) for $386,400.
- Transaction Financing: $295,000 borrowed from Rivington Tecnologies Ltd. at 2% annual interest, due February 28, 2005; secured by 1,520,000 shares.
Material Changes
- Change in Control: Jeannine Karklins, the former principal shareholder, President, Treasurer, and Secretary, sold 97% of the company's stock to Panetta Partners, Ltd.
- Management Resignation: Ms. Karklins resigned from all officer and director positions.
- New Leadership: Christoph Bruening was appointed as the sole director, President, Secretary, and Treasurer. Mr. Bruening has a background in biopharmaceuticals (Callisto Pharmaceuticals) and investor relations.
Outlook and Management Commentary
Mr. Bruening stated he will evaluate the registrant's current business plan to determine its viability and will assess potential acquisitions for the registrant. The filing notes that the company has not reported any revenue and holds minimal assets. No specific financial guidance or pro forma information was provided in this report.
Investor Verification Checklist
- Verify the discrepancy between the request metadata (Cardiff Oncology) and the filing content (Used Kar Parts, Inc.).
- Confirm the viability of the new management's plan to pivot or acquire assets given the company's accumulated deficit and lack of revenue.
- Review the terms of the $295,000 loan from Rivington Tecnologies Ltd., specifically the pledge of 1,520,000 shares as collateral.
- Check for any pending legal proceedings, though the filing states none exist.